Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma

Choi, Yeon-Seok; Kim, Kihwan; Jeong, Byeong‐Ho; Lee, Kyung Jong; Kim, Hojoong; Kwon, O Jung; Kim, Young Tae; Choi, Yoon‐La; Lee, Ho Yun; Um, Sang‐Won

doi:10.21037/jtd-20-1716

Cited by 8 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Babiy et al said that the latest statistics in China in 2017 showed that the number of lung cancer cases was 730,000, the number of deaths was 590,000, and the two figures also topped the list [ 3 ]. Choi et al said that known risk factors for lung cancer include smoking and air pollution, and the incidence of lung cancer is increasing year by year with the increase of tobacco abuse and environmental pollution worldwide [ 4 ]. Blackstone and El-Aini stated that surgical resection is the preferred treatment for early stage lung cancer, and it is mainly treated by a combination of surgery, radiotherapy, and chemotherapy [ 5 ].…”

Section: Literature Reviewmentioning

confidence: 99%

Diagnostic Efficacy of CT Radiomic Features in Pulmonary Invasive Mucinous Adenocarcinoma

Sheng

Zhou

et al. 2022

Scanning

View full text Add to dashboard Cite

In order to solve the problem of the effect of CT images on the diagnosis of lungs, the authors proposed a method for the diagnosis of invasive mucinous adenocarcinoma of the lungs based on CT radiomic features, and the modified method is found by reviewing past cases: among the 34 cases of primary pulmonary lymphoma, 12 cases were nodular mass type, 19 cases were nonnodular mass type, and 3 cases were mixed type; 13 cases involved bilateral lung lobes, 7 cases involved right lung, and 4 cases involved left lung example. There were 17 cases of tumor consolidation density shadow, 17 cases of mixed density shadow, the average CT value was about 32HU, 15 cases of cavitation sign, 6 cases of cavity, 9 cases of angiography sign, 30 cases of air bronchus sign, 22 cases of bronchiectasis, bronchial stenosis or amputation in 8 cases, pleural effusion in 12 cases, lymph node enlargement in 15 cases, and pleural metastasis in 2 cases. The final pathological results included 24 cases of membrane-associated lymphoid tissue (MALT) lymphoma, 9 cases of diffuse large B-cell lymphoma (DLBCL), and 1 case of T-cell lymphoma. The CT manifestations of primary pulmonary lymphoma (PPL) are diverse and do not have obvious specificity, the imaging manifestations are correlated with pathological types, and air bronchial signs, bronchiectasis, angiography signs, and other signs are used for the diagnosis of PPL. This is of great significance for the diagnosis of PPL.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Diagnostic Efficacy of CT Radiomic Features in Pulmonary Invasive Mucinous Adenocarcinoma

Sheng

Zhou

et al. 2022

Scanning

View full text Add to dashboard Cite

show abstract

“…In previous studies of genetic alterations in lung adenocarcinoma manifesting as SSNs, EGFR mutations were the major driver mutations (frequency of 36-89%) (11,(51)(52)(53)(54)(55). The differences in EGFR mutation frequency among these studies may be partly explained by differences in study populations (Asian vs. Caucasian), detection methods (polymerase chain reaction vs. next generation sequencing), and nodule subtypes (pure GGNs vs. PSNs).…”

Section: Genetic Alterations In Lung Adenocarcinoma Manifesting As Ssnsmentioning

confidence: 99%

“…The differences in EGFR mutation frequency among these studies may be partly explained by differences in study populations (Asian vs. Caucasian), detection methods (polymerase chain reaction vs. next generation sequencing), and nodule subtypes (pure GGNs vs. PSNs). Other genetic alterations identified in lung adenocarcinoma manifesting as SSNs included KRAS mutations, HER2 mutations, BRAF mutations, ALK rearrangement, and ROS1 rearrangement ( 11 , 53 - 58 ).…”

Section: Genetic Alterations In Lung Adenocarcinoma Manifesting As Ssnsmentioning

confidence: 99%

See 1 more Smart Citation

A narrative review of the clinical approach to subsolid pulmonary nodules

Kim¹,

Um²

2023

Ann Transl Med

Self Cite

View full text Add to dashboard Cite

Background and Objective The widespread use of chest computed tomography (CT) for lung cancer screening has led to increased detection of subsolid pulmonary nodules. The management of subsolid nodules (SSNs) is challenging since they are likely to grow slowly and a long-term follow-up is needed. In this review, we discuss the characteristics, natural history, genetic features, surveillance, and management of SSNs. Methods PubMed and Google Scholar were searched to identify relevant articles published in English between January 1998 and December 2022 using the following keywords: “subsolid nodule”, “ground-glass nodule (GGN)”, and “part-solid nodule (PSN)”. Key Content and Findings The differential diagnosis of SSNs includes transient inflammatory lesions, focal fibrosis, and premalignant or malignant lesions. Long-term CT surveillance follow-up is needed to manage SSNs that persist for >3 months. Although most SSNs have an indolent clinical course, PSNs may have a more aggressive clinical course than pure GGNs. The proportion of growth and the time to grow is higher and shorter in PSN than pure GGN. In lung adenocarcinoma manifesting as SSNs, EGFR mutations were the major driver mutations. Guidelines are available for the management of incidentally detected and screening-detected SSNs. The size, solidity, location, and number of SSNs are important factors in determining the need for surveillance and surgical resection, as well as the interval of follow-up. Positron emission tomography/CT and brain magnetic resonance imaging (MRI) are not recommended for the diagnosis of SSNs, especially for pure GGNs. Periodic CT surveillance and lung-sparing surgery are the main strategies for the management of persistent SSNs. Nonsurgical treatment options for persistent SSNs include stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA). For multifocal SSNs, the timing of repeated CT scans and the need for surgical treatment are decided based on the most dominant SSN(s). Conclusions The SSN is a heterogeneous disease and a personalized medicine approach is required in the future. Future studies of SSNs should focus on their natural history, optimal follow-up duration, genetic features, and surgical and nonsurgical treatments to improve the corresponding clinical management. All these efforts will lead to the personalized medicine approach for the SSNs.

show abstract

“…In subgroup analyses, the median follow-up duration of patients with cLy1, cLy2, cLy3, and cLy4 were 60 , 38 , 16 , and 12 [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] months, respectively. The 5-year OS rates of these patients were 54% (95% CI: 38-76%), 35% (95% CI: 23-54%), 12% (95% CI: 4-34%), and 11% (95% CI: 2-71%), respectively (Figure 2B).…”

Section: Follow-up and Overall Survivalmentioning

confidence: 99%

Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer

Im¹,

Lee²,

Lee³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background:The eighth edition of the TNM classification for lung cancer does not provide a definite guideline for pulmonary lymphangitic carcinomatosis. The purpose of this retrospective case-control study is to evaluate the prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer compared with those with intrapulmonary metastases.Methods: Non-small cell lung cancer (NSCLC) patients with pulmonary lymphangitic carcinomatosis detected on chest computed tomography scan during staging evaluation between 2000 and 2016 were included. The extent of pulmonary lymphangitic carcinomatosis was classified as being around the primary tumor (cLy1), at a distance from the tumor but confined to the same lobe (cLy2), in other ipsilateral lobes (cLy3), or affecting the contralateral lung (cLy4). Overall survival rates of the subjects were compared with those with intrapulmonary metastases.Results: A total of 103 subjects with pulmonary lymphangitic carcinomatosis were analysed. The 5-year overall survival rates of the subjects with pulmonary lymphangitic carcinomatosis (n=103) and intrapulmonary metastases (n=111) were 33% and 21%, respectively. The 5-year overall survival rates of cLy1 (n=28), cLy2 (n=40), cLy3 (n=26) and cLy4 (n=9) were 54%, 35%, 12% and 11%, respectively. On multivariable analyses after adjusting for possible confounders, the subjects with cLy1 and cLy2 had better overall survival (adjusted hazard ratio for death, 0.34 and 0.49; 95% confidence interval, 0.24-0.73 and 0.30-0.80; P<0.001 and 0.004, respectively) and the subjects with cLy4 had worse overall survival (adjusted hazard ratio, 2.21; 95% confidence interval, 1.03-4.70; P=0.040) compared with those with intrapulmonary metastases. Conclusions:The subjects with cLy1/2 had better overall survival than those with cLy3/4 or intrapulmonary metastases. cLy1/2 seems to be a T descriptor (T3/4) rather than an M1 descriptor.

show abstract

Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma

Cited by 8 publications

References 37 publications

Diagnostic Efficacy of CT Radiomic Features in Pulmonary Invasive Mucinous Adenocarcinoma

Diagnostic Efficacy of CT Radiomic Features in Pulmonary Invasive Mucinous Adenocarcinoma

A narrative review of the clinical approach to subsolid pulmonary nodules

Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer

Contact Info

Product

Resources

About